

30 May 2022

Intra-Vitreous Treatments in Ophthalmology

1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:

- Aflibercept 3724
- Bevacizumab 5
- Brolucizumab 0
- Dexamethasone 22
- Ranibizumab 1682

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept 83
- Bevacizumab 0
- Brolucizumab 0
- Dexamethasone 8
- Ranibizumab 34

3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept 487
- Bevacizumab 0
- Dexamethasone 1
- Ranibizumab 434

4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept 527
- Bevacizumab 2
- Dexamethasone 6
- Ranibizumab 180